Hims & Hers Health (NYSE:HIMS) Shares Up 10.8% – Still a Buy?

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price was up 10.8% during mid-day trading on Wednesday . The company traded as high as $29.91 and last traded at $30.3360. Approximately 11,227,575 shares traded hands during mid-day trading, a decline of 57% from the average daily volume of 26,227,777 shares. The stock had previously closed at $27.39.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of research reports. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. TD Cowen increased their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research note on Friday, August 7th. Finally, Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $32.43.

Hims & Hers Health Stock Up 1.9%

The stock has a market capitalization of $7.58 billion, a price-to-earnings ratio of -51.54 and a beta of 2.40. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. The stock has a 50 day moving average price of $32.23 and a 200 day moving average price of $26.09.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The firm had revenue of $753.21 million during the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business’s quarterly revenue was up 38.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. As a group, analysts forecast that Hims & Hers Health, Inc. will post -0.05 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 4,938 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $29.99, for a total value of $148,090.62. Following the completion of the transaction, the chief financial officer directly owned 264,117 shares in the company, valued at approximately $7,920,868.83. This represents a 1.84% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. The trade was a 11.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 186,769 shares of company stock worth $6,035,648. Company insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new position in Hims & Hers Health during the fourth quarter worth $11,187,000. Cunning Capital Partners LP bought a new position in Hims & Hers Health during the fourth quarter worth $1,110,000. Norges Bank acquired a new stake in Hims & Hers Health in the fourth quarter worth $62,153,000. Finally, Virtu Financial LLC acquired a new stake in Hims & Hers Health in the fourth quarter worth $1,937,000. 63.52% of the stock is owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.